Stock Rating Runner: Mallinckrodt plc (NYSE:MNK) Stock Rating Kept by Analysts at Mizuho; The $85 Target Indicates 62.15% Potential

November 30, 2016 - By Louis Casey

Stock Rating Runner: Mallinckrodt plc (NYSE:MNK) Stock Rating Kept by Analysts at Mizuho; The $85 Target Indicates 62.15% Potential

Mallinckrodt plc (NYSE:MNK) Rating

Mallinckrodt plc (NYSE:MNK) had its stock rating noted as Buy by analysts at Mizuho. Mizuho currently has a $85 TP on the $5.69B market cap company or 62.15% upside potential. This was disclosed to clients in a report on Wednesday morning.

Mallinckrodt PLC (NYSE:MNK) Ratings Coverage

Out of 16 analysts covering Mallinckrodt (NYSE:MNK), 13 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 81% are positive. $218 is the highest target while $72 is the lowest. The $104 average target is 98.40% above today’s ($52.42) stock price. Mallinckrodt has been the topic of 33 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Mallinckrodt PLC (NYSE:MNK) has “Neutral” rating given on Wednesday, May 4 by JP Morgan. The stock has “Neutral” rating given by Nomura on Tuesday, September 29. The company was maintained on Thursday, September 29 by Mizuho. Deutsche Bank maintained Mallinckrodt PLC (NYSE:MNK) rating on Wednesday, October 7. Deutsche Bank has “Buy” rating and $89 price target. The stock of Mallinckrodt PLC (NYSE:MNK) earned “Outperform” rating by Northland Capital on Wednesday, November 11. The rating was maintained by Piper Jaffray on Wednesday, August 24 with “Overweight”. The stock of Mallinckrodt PLC (NYSE:MNK) earned “Overweight” rating by Barclays Capital on Wednesday, August 5. The firm has “Outperform” rating by Leerink Swann given on Wednesday, October 7. As per Wednesday, June 29, the company rating was initiated by BMO Capital Markets. Deutsche Bank maintained Mallinckrodt PLC (NYSE:MNK) rating on Wednesday, August 31. Deutsche Bank has “Buy” rating and $84 price target.

The stock decreased 9.10% or $5.25 during the last trading session, hitting $52.42. About 582 shares traded hands. Mallinckrodt PLC (NYSE:MNK) has declined 19.83% since April 27, 2016 and is downtrending. It has underperformed by 25.06% the S&P500.

Insitutional Activity: The institutional sentiment increased to 0.91 in 2016 Q2. Its up 0.08, from 0.83 in 2016Q1. The ratio improved, as 45 funds sold all Mallinckrodt PLC shares owned while 146 reduced positions. 45 funds bought stakes while 113 increased positions. They now own 100.83 million shares or 4.32% less from 105.38 million shares in 2016Q1.

California State Teachers Retirement System accumulated 0.03% or 238,178 shares. Diam Ltd holds 0.17% of its portfolio in Mallinckrodt PLC (NYSE:MNK) for 192,473 shares. Piershale Inc owns 22 shares or 0% of their US portfolio. Engineers Gate Manager L P has invested 0.38% of its portfolio in Mallinckrodt PLC (NYSE:MNK). Hudock Gru Ltd Liability Corporation holds 0% or 35 shares in its portfolio. Wells Fargo And Mn has 0% invested in the company for 95,191 shares. Cornerstone Advsr, a Washington-based fund reported 42 shares. Tradewinds Capital Mngmt Ltd Llc has invested 0% of its portfolio in Mallinckrodt PLC (NYSE:MNK). Tudor Corporation Et Al last reported 5,434 shares in the company. Moreover, Oxford Asset Mngmt has 0.51% invested in Mallinckrodt PLC (NYSE:MNK) for 199,427 shares. holds 0% of its portfolio in Mallinckrodt PLC (NYSE:MNK) for 119 shares. The Connecticut-based Everpoint Asset Mngmt Ltd Liability has invested 0.37% in Mallinckrodt PLC (NYSE:MNK). Invsts Cap Advisory accumulated 0.1% or 8,710 shares. Neuberger Berman Grp Incorporated Lc accumulated 17,000 shares or 0% of the stock. Cwm Ltd Liability last reported 0% of its portfolio in the stock.

Mallinckrodt public limited company is engaged in the specialty pharmaceuticals and nuclear imaging business. The company has a market cap of $5.69 billion. The Firm develops, makes, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. It has a 11.51 P/E ratio. The Company’s divisions include Specialty Brands, Specialty Generics and Nuclear Imaging.

According to Zacks Investment Research, “Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company’s Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.”

More notable recent Mallinckrodt PLC (NYSE:MNK) news were published by: Cnbc.com which released: “Mallinckrodt plagued by ‘production issues,’ falls about 9%” on November 29, 2016, also Reuters.com with their article: “BRIEF-Mallinckrodt Plc reports 2016 fourth quarter results” published on November 29, 2016, Nasdaq.com published: “Earnings Reaction History: Mallinckrodt plc, 40.0% Follow-Through Indicator, 4 …” on November 29, 2016. More interesting news about Mallinckrodt PLC (NYSE:MNK) were released by: Investorplace.com and their article: “Why Lowe’s Companies, Inc. (LOW), PDL BioPharma Inc (PDLI) and Mallinckrodt …” published on November 16, 2016 as well as Cnbc.com‘s news article titled: “Mallinckrodt shares tank as short-seller Andrew Left claims CEO commits fraud” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>